Nusantics

About:

A precision molecular diagnostics start-up that develops PCR and NGS-based solutions for both human and animal applications

Website: http://www.nusantics.com/

Top Investors: East Ventures, Illumina Accelerator

Description:

Nusantics is a precision molecular diagnostics startup from Indonesia; we develop PCR and Next Generation Sequencing-based solutions to improve healthcare outcomes in both human and animal applications. We offer 3 types of products; single pathogen molecular diagnostics, syndromic molecular diagnostics, and microbiome diagnostics (NGS)

Total Funding Amount:

$2.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Jakarta, Jakarta Raya, Indonesia

Founded Date:

2020-01-01

Contact Email:

hello(AT)nusantics.com

Founders:

Revata Utama, Sharlini Eriza Putri

Number of Employees:

51-100

Last Funding Date:

2022-09-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai